158 related articles for article (PubMed ID: 22019606)
1. [Effectiveness of therapeutic erythrocytapheresis to achieve iron depletion in hereditary type 1 hemochromatosis: report of 30 cases].
Poullin P; Lefèvre PA
Transfus Clin Biol; 2011 Dec; 18(5-6):553-8. PubMed ID: 22019606
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic erythrocytapheresis in the initial treatment of hereditary hemochromatosis.
Rehácek V; Bláha M; Jirousová H; Cernohorská J; Papousek P
Acta Medica (Hradec Kralove); 2012; 55(4):180-5. PubMed ID: 23631289
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of erythrocytapheresis and low-dose erythropoietin for treatment of hemochromatosis.
Brückl D; Kamhieh-Milz S; Kamhieh-Milz J; Salama A
J Clin Apher; 2017 Jun; 32(3):170-174. PubMed ID: 27271482
[TBL] [Abstract][Full Text] [Related]
4. Effect of Native American ancestry on iron-related phenotypes of Alabama hemochromatosis probands with HFE C282Y homozygosity.
Barton JC; Barton EH; Acton RT
BMC Med Genet; 2006 Mar; 7():22. PubMed ID: 16533407
[TBL] [Abstract][Full Text] [Related]
5. Repeated isovolemic large-volume erythrocytapheresis in the treatment of idiopathic hemochromatosis.
Kellner H; Zoller WG
Z Gastroenterol; 1992 Nov; 30(11):779-83. PubMed ID: 1471384
[TBL] [Abstract][Full Text] [Related]
6. Reduction of body iron in HFE-related haemochromatosis and moderate iron overload (Mi-Iron): a multicentre, participant-blinded, randomised controlled trial.
Ong SY; Gurrin LC; Dolling L; Dixon J; Nicoll AJ; Wolthuizen M; Wood EM; Anderson GJ; Ramm GA; Allen KJ; Olynyk JK; Crawford D; Ramm LE; Gow P; Durrant S; Powell LW; Delatycki MB
Lancet Haematol; 2017 Dec; 4(12):e607-e614. PubMed ID: 29195602
[TBL] [Abstract][Full Text] [Related]
7. [Comparison between phlebotomy and erythrocytapheresis of iron overload in patients with HFE gene mutations].
Fernández-Mosteirín N; Salvador-Osuna C; García-Erce JA; Orna E; Pérez-Lungmus G; Giralt M
Med Clin (Barc); 2006 Sep; 127(11):409-12. PubMed ID: 17020684
[TBL] [Abstract][Full Text] [Related]
8. [Hereditary hemochromatosis].
Dantas W
Rev Gastroenterol Peru; 2001; 21(1):42-55. PubMed ID: 12170286
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of death from iron overload among 422 treated probands with HFE hemochromatosis and serum levels of ferritin greater than 1000 μg/L at diagnosis.
Barton JC; Barton JC; Acton RT; So J; Chan S; Adams PC
Clin Gastroenterol Hepatol; 2012 Apr; 10(4):412-6. PubMed ID: 22265917
[TBL] [Abstract][Full Text] [Related]
10. Correlation between genotype and phenotype in hereditary hemochromatosis: analysis of 61 cases.
Sham RL; Ou CY; Cappuccio J; Braggins C; Dunnigan K; Phatak PD
Blood Cells Mol Dis; 1997 Aug; 23(2):314-20. PubMed ID: 9410475
[TBL] [Abstract][Full Text] [Related]
11. Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial.
Rombout-Sestrienkova E; Nieman FH; Essers BA; van Noord PA; Janssen MC; van Deursen CT; Bos LP; Rombout F; van den Braak R; de Leeuw PW; Koek GH
Transfusion; 2012 Mar; 52(3):470-7. PubMed ID: 21848963
[TBL] [Abstract][Full Text] [Related]
12. Iron-overload-related disease in HFE hereditary hemochromatosis.
Allen KJ; Gurrin LC; Constantine CC; Osborne NJ; Delatycki MB; Nicoll AJ; McLaren CE; Bahlo M; Nisselle AE; Vulpe CD; Anderson GJ; Southey MC; Giles GG; English DR; Hopper JL; Olynyk JK; Powell LW; Gertig DM
N Engl J Med; 2008 Jan; 358(3):221-30. PubMed ID: 18199861
[TBL] [Abstract][Full Text] [Related]
13. Hemochromatosis and iron-overload screening in a racially diverse population.
Adams PC; Reboussin DM; Barton JC; McLaren CE; Eckfeldt JH; McLaren GD; Dawkins FW; Acton RT; Harris EL; Gordeuk VR; Leiendecker-Foster C; Speechley M; Snively BM; Holup JL; Thomson E; Sholinsky P;
N Engl J Med; 2005 Apr; 352(17):1769-78. PubMed ID: 15858186
[TBL] [Abstract][Full Text] [Related]
14. HLA haplotype A*03-B*07 in hemochromatosis probands with HFE C282Y homozygosity: frequency disparity in men and women and lack of association with severity of iron overload.
Barton JC; Wiener HW; Acton RT; Go RC
Blood Cells Mol Dis; 2005; 34(1):38-47. PubMed ID: 15607698
[TBL] [Abstract][Full Text] [Related]
15. Proton Pump Inhibitors Reduce the Frequency of Phlebotomy in Patients With Hereditary Hemochromatosis.
van Aerts RM; van Deursen CT; Koek GH
Clin Gastroenterol Hepatol; 2016 Jan; 14(1):147-52. PubMed ID: 26240005
[TBL] [Abstract][Full Text] [Related]
16. Elevated MCP-1 serum levels are associated with the H63D mutation and not the C282Y mutation in hereditary hemochromatosis.
Lawless MW; White M; Mankan AK; O'Dwyer MJ; Norris S
Tissue Antigens; 2007 Oct; 70(4):294-300. PubMed ID: 17767550
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and treatment of hereditary hemochromatosis: an update.
Kanwar P; Kowdley KV
Expert Rev Gastroenterol Hepatol; 2013 Aug; 7(6):517-30. PubMed ID: 23985001
[TBL] [Abstract][Full Text] [Related]
18. Serial serum ferritin measurements in untreated HFE C282Y homozygotes in the Hemochromatosis and Iron Overload Screening Study.
Adams PC; Reboussin DM; Barton JC; Acton RT; Speechley M; Leiendecker-Foster C; Meenan R; Passmore L; McLaren CE; McLaren GD; Gordeuk V; Dawkins F; Eckfeldt JH
Int J Lab Hematol; 2008 Aug; 30(4):300-5. PubMed ID: 18665827
[TBL] [Abstract][Full Text] [Related]
19. Course of iron parameters in HFE-hemochromatosis patients during initial treatment with erythrocytapheresis compared to phlebotomy.
Rombout-Sestrienkova E; Koek GH; Neslo R; van Kraaij M; Menheere PP; Masclee A; Swinkels DW
J Clin Apher; 2016 Dec; 31(6):564-570. PubMed ID: 26878994
[TBL] [Abstract][Full Text] [Related]
20. Erythrocytapheresis plus erythropoietin: an alternative therapy for selected patients with hemochromatosis and severe organ damage.
Mariani R; Pelucchi S; Perseghin P; Corengia C; Piperno A
Haematologica; 2005 May; 90(5):717-8. PubMed ID: 15921401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
